Literature DB >> 8869476

The economics of immune tolerance and treatment of hemophiliacs with inhibitors.

C M Kessler1, L M Aledort.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8869476

Source DB:  PubMed          Journal:  Vox Sang        ISSN： 0042-9007            Impact factor:   2.144


× No keyword cloud information.
  3 in total

1.  Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A.

Authors:  Farhad Lotfi; Hamid Talebianpour; Khosro Keshavarz; Fatemeh Emadi; Mohammad Reza Bordbar; Peivand Bastani
Journal:  Daru       Date:  2020-04-22       Impact factor: 3.117

Review 2.  Immune tolerance therapy for haemophilia.

Authors:  A Y Ho; S E Height; M P Smith
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

3.  Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran.

Authors:  Hamid Reza Rasekh; Ali Imani; Mehran Karimi; Mina Golestani
Journal:  Clinicoecon Outcomes Res       Date:  2011-11-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.